Dermatology · Las Vegas, NV
NPI
1447276175
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
653 N Town Center Dr, Ste #414
Las Vegas, NV, 89144
Phone (702) 456-3120
Groups this clinician bills Medicare through
Medicare paid, 2024
$314K
5,201 services
Medicare patients, 2024
762
Average age 75
Drug cost, 2024
$1.7M
1,468 prescriptions
Company payments, 2025
$281K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harry Greenberg was code 17003 (destruction skin lesion), 1,651 times for 266 patients. In total Harry Greenberg billed 5,201 services in 36 codes, and Medicare paid $314K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,651 | 266 | $4.92 | $8,122 |
| 99214 Office E&M - Established | Office | 1,218 | 660 | $90.22 | $110K |
| 17000 Destruction Skin Lesion | Office | 482 | 335 | $37.16 | $18K |
| 17110 Destruction Skin Lesion | Office | 444 | 322 | $83.14 | $37K |
| 99204 Office E&M - New | Office | 158 | 158 | $113.18 | $18K |
| 11102 Skin Biopsy | Office | 121 | 110 | $58.97 | $7,135 |
| 17004 Destruction Skin Lesion | Office | 116 | 73 | $130.09 | $15K |
| 17111 Destruction Skin Lesion | Office | 55 | 47 | $101.02 | $5,556 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 47 | 41 | $12.86 | $604 |
| 96401 Chemotherapy Administration | Office | 27 | 13 | $50.10 | $1,353 |
| 10061 Skin | Office | 26 | 24 | $164.57 | $4,279 |
By year: 2022 $294K for 5,459 services; 2023 $407K for 6,396 services; 2024 $314K for 5,201 services.
Medicare prescription drug claims, 2024
In 2024, the drug Harry Greenberg prescribed most often to Medicare patients was Ketoconazole, with 171 prescriptions and refills. In total Harry Greenberg wrote 1,468 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 171 | 173 | 77 | $3,576 |
| Tacrolimus Generic | 135 | 135 | 84 | $18K |
| Mupirocin Generic | 119 | 119 | 73 | $650 |
| Valacyclovir Valacyclovir Hcl | 118 | 145 | 31 | $2,256 |
| Triamcinolone Acetonide Generic | 85 | 88 | 57 | $1,454 |
| Zoryve Roflumilast | 85 | 90 | 32 | $73K |
| Dupixent Pen Dupilumab | 65 | 79 | 11 | $302K |
| Hydroxyzine Hcl Generic | 47 | 65 | 23 | $804 |
| Ciclopirox Generic | 44 | 44 | 21 | $1,584 |
| Fluorouracil Generic | 40 | 40 | 37 | $2,979 |
| Doxycycline Hyclate Generic | 37 | 43 | 23 | $953 |
| Otezla Apremilast | 36 | 36 | Under 11 | $161K |
| Imiquimod Generic | 33 | 36 | 18 | $899 |
| Dupixent Syringe Dupilumab | 27 | 27 | Under 11 | $102K |
| Clindamycin Phosphate Generic | 25 | 27 | Under 11 | $745 |
Brand drugs: 400 claims; generic drugs: 1,068 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harry Greenberg $281K ($280K in general payments such as food, travel and fees and $1,086 for research) from 25 companies. The largest payer was Arcutis Biotherapeutics, Inc. with $37K.
| Company | Payments | Amount |
|---|---|---|
| Arcutis Biotherapeutics, Inc. ARQT | 51 | $37K |
| LEO Pharma Inc. | 48 | $36K |
| Galderma Laboratories, L.P. GALD.SW | 57 | $33K |
| Organon LLC OGN | 30 | $32K |
| Incyte Corporation INCY | 44 | $25K |
| Janssen Biotech, Inc. JNJ | 37 | $21K |
| UCB, Inc. UCB.BR | 26 | $18K |
| E.R. Squibb & Sons, L.L.C. BMY | 28 | $16K |
| Abbvie Inc. ABBV | 30 | $16K |
| Regeneron Healthcare Solutions, Inc. REGN | 31 | $14K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.